Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Summary of findings ‐ Ciklavit® vs placebo

Any adverse events including hepatic and renal toxicity · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low

Summary of findings ‐ Ciklavit® vs placebo

Frequency of blood transfusion · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Ciklavit® vs placebo

Level of anaemia: packed cell volume · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low

Summary of findings ‐ Ciklavit® vs placebo

Quality of life measures · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Niprisan® vs placebo

Frequency of severe complications of SCD · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
70 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Frequency of hospital admissions from severe complications of SCD · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
70 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Any adverse events including hepatic and renal toxicity · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
80 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Frequency of blood transfusion · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Niprisan® vs placebo

Change in haemoglobin level from baseline · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
52 participants
Low

Summary of findings ‐ Niprisan® vs placebo

Quality of life measures: self reported health, absence from work or school · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
70 participants
Very low

Summary of findings ‐ Ciklavit® vs placebo

Frequency, severity or duration of painful crises · people with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low

Summary of findings ‐ Ciklavit® vs placebo

Frequency of severe complications of SCD · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: β‐carotene vs placebo

Number of days on antibiotics for acute exacerbations · adults and children with cystic fibrosis

Summary of findings: β‐carotene showed no clear difference in pulmonary exacerbations Days of antibiotic use compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Summary of findings: β‐carotene vs placebo

FEV1 % predicted · adults and children with cystic fibrosis

Summary of findings: β‐carotene showed no clear difference in respiratory function absolute FEV1 % predicted compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Summary of findings: β‐carotene vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Summary of findings: β‐carotene vs placebo

Need for antibiotics see pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: β‐carotene vs placebo

QoL · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: β‐carotene vs placebo

Sputum microbiology · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: β‐carotene vs placebo

Inflammatory markers · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ ivacaftor vs placebo

Survival · adults and children with cystic fibrosis and with the F508del CFTR mutation

1 finding from 1 review

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 140 participants
GRADE not reported